TRAIL on trial: preclinical advances in cancer therapy.

  title={TRAIL on trial: preclinical advances in cancer therapy.},
  author={Daniel W. Stuckey and Khalid Shah},
  journal={Trends in molecular medicine},
  volume={19 11},
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 70 extracted citations

Similar Papers

Loading similar papers…